David Aaron Lehman sold $17k of LUNG
GENERAL COUNSEL at Pulmonx Corp. 12,237 shares at an average of $1.43, traded Mar 2, 2026, filed Mar 4, 2026.
Score components
- +15RoleOfficer
- 0Trade size$17k at market
- 0Share of holdings soldSold 4.8% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.6%, 3m +5.6%, 6m +58.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001354228-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | SOpen-market sale Common Stock | -1,163 | $1.43 | $1,663 | 251,829 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock | -4,433 | $1.43 | $6,339 | 247,396 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock | -2,590 | $1.43 | $3,704 | 244,806 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock | -4,051 | $1.43 | $5,793 | 240,755 | Mar 4, 2026 |
| Mar 2, 2026 | AGrant or award Common Stock | +150,000 | $0.00 | $0 | 390,755 | Mar 4, 2026 |
Related signals
Other insiders at Pulmonx Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Pulmonx Corp | Glendon E. French III President and CEO | $95k 41,882 shares | -4% | |
| 35Weak | Pulmonx Corp | David Aaron Lehman General Counsel | $32k 14,334 shares | -4% | |
| 30Weak | Pulmonx Corp | Geoffrey Beran Rose Chief Commercial Officer | $18k 7,879 shares | -2% | |
| 35Weak | Pulmonx Corp | Srikanth Radhakrishnan Chief Science & Techn. Officer | $32k 14,245 shares | -4% | |
| 49Moderate | Pulmonx Corp | Glendon E. French III President and CEO | $87k 56,149 shares | -5% | |
| 30Weak | Pulmonx Corp | David Aaron Lehman GENERAL COUNSEL | $22k 14,594 shares | -4% | |
| 30Weak | Pulmonx Corp | Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | $12k 8,023 shares | -2% | |
| 30Weak | Pulmonx Corp | Srikanth Radhakrishnan Chief Science &Techn. Officer | $22k 14,497 shares | -4% | |
| 50Moderate | Pulmonx Corp | Glendon E. French III President and CEO | $97k 67,813 shares | -5% | |
| 30Weak | Pulmonx Corp | Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | $11k 7,732 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.